Teva Respiratory, the U.S.-based respiratory subsidiary of Israeli Teva Pharmaceutical Industries announced that the FDA has approved its quick relief inhaler ProAir HFA with a dose counter, for the treatment or prevention of breathing disorders in patients four years of age and older. The dose counter is designed to help patients suffering drom disorders such as , Chronic Obstructive Pulmonary Disease (COPD) and Exercise-Induced Bronchospasm (EIB), keep track of the number of doses remaining in the canister. The new product will be commercially available later this year. View and Share
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli Startup Rings Closing Bell At Nasdaq in NYC
March 28, 2024
Israeli, US Companies Unite To Make More Milk From Mushrooms
March 27, 2024
Facebook comments